Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9905251 | Cancer Letters | 2005 | 4 Pages |
Abstract
The clinical diversity of Neuroblastomas (NBs) was discriminated into three groups with high sensitivity and specificity to patient's outcome. The 'high risk' NB is defined with any of following conditions, MYCN amplification or unfavorable histology of International Neuroblastoma Pathological Classification (INPC) or low Ha-ras/trk A expression. The 'low risk' NB is defined with all following conditions, single copy of MYCN and INPC favorable histology and high Ha-ras/trk A expression and localized tumor. The remaining NBs were classified into 'intermediate risk' ones. According to these criteria, the diversity of the 248 mass-screening NBs was shown with variety progressive risk; 40% were classified in low risk group, 25% were in high risk group and 35% were in intermediate risk group.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Takeo Tanaka, Tomoko Iehara, Tohru Sugimoto, Minoru Hamasaki, Satoshi Teramukai, Yoshiaki Tsuchida, Michio Kaneko, Tadashi Sawada,